Publications by authors named "Haytham Noureldeen"
Article Synopsis
- Early recognition of sepsis and timely treatment are essential for better patient outcomes, with quality improvement programs showing positive effects in sepsis care.
- A multidisciplinary sepsis task force implemented a program over 24 months, focusing on screening and monitoring through a sepsis flowsheet in the emergency department.
- Key improvements included a rise in timely antibiotic administration from 44% to 84%, significant enhancements in fluid and lab test administration, and a reduction in mortality rates from 32% to 21%.
Background: Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (COVID-19), and these studies demonstrate conflicting results. Our study aimed to determine the association between tocilizumab treatment and microbial isolation and emergence of multidrug-resistant bacteria in critically ill patients with COVID-19.
View Article and Find Full Text PDFPurpose: To evaluate the effectiveness and safety of the optimal tocilizumab dosing regimen.
Methods: A two-center, retrospective cohort study, for COVID19 critically ill patients admitted to the intensive care units (ICUs). We included critically ill patients aged 18 years or older who received tocilizumab during ICU stay.